Vertex Pharmaceuticals (VRTX) Receives Daily Media Impact Rating of 0.22
News headlines about Vertex Pharmaceuticals (NASDAQ:VRTX) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vertex Pharmaceuticals earned a news impact score of 0.22 on Accern’s scale. Accern also gave news headlines about the pharmaceutical company an impact score of 45.1449395756757 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern’s rankings:
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) SVP Paul M. Silva Sells 1,289 Shares (americanbankingnews.com)
- Insider Selling: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CFO Sells 4,250 Shares of Stock (americanbankingnews.com)
- Why Vertex Pharmaceuticals Incorporated (VRTX) Will Keep Rolling Higher (investorplace.com)
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Cut to Hold at Zacks Investment Research (americanbankingnews.com)
- Brokerages Expect Vertex Pharmaceuticals Incorporated (VRTX) Will Post Quarterly Sales of $512.79 Million (americanbankingnews.com)
A number of research firms have commented on VRTX. UBS AG restated a “buy” rating and set a $135.00 target price (up previously from $132.00) on shares of Vertex Pharmaceuticals in a research note on Friday, May 19th. Vetr upgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $181.00 target price on the stock in a research note on Monday, July 31st. Cowen and Company reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, August 1st. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a report on Sunday, April 30th. Finally, Maxim Group set a $195.00 price objective on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, July 27th. Five analysts have rated the stock with a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the stock. Vertex Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $162.88.
Vertex Pharmaceuticals (VRTX) traded down 0.44% during mid-day trading on Wednesday, hitting $152.58. The stock had a trading volume of 1,037,955 shares. Vertex Pharmaceuticals has a one year low of $71.46 and a one year high of $167.86. The firm’s 50-day moving average price is $140.44 and its 200 day moving average price is $112.89. The company has a market cap of $38.47 billion, a PE ratio of 146.57 and a beta of 1.77.
Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.33. The company had revenue of $544.10 million for the quarter, compared to analyst estimates of $489.95 million. Vertex Pharmaceuticals had a return on equity of 4.64% and a net margin of 12.05%. Vertex Pharmaceuticals’s revenue for the quarter was up 26.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.24 EPS. On average, equities research analysts anticipate that Vertex Pharmaceuticals will post $1.59 EPS for the current year.
In other Vertex Pharmaceuticals news, EVP Stuart A. Arbuckle sold 70,969 shares of the stock in a transaction dated Friday, June 2nd. The stock was sold at an average price of $128.06, for a total value of $9,088,290.14. Following the sale, the executive vice president now owns 145,061 shares of the company’s stock, valued at approximately $18,576,511.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Ian F. Smith sold 4,250 shares of the stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $155.39, for a total value of $660,407.50. Following the completion of the sale, the chief financial officer now directly owns 120,138 shares in the company, valued at approximately $18,668,243.82. The disclosure for this sale can be found here. Insiders sold a total of 751,042 shares of company stock worth $113,078,257 in the last ninety days. 1.80% of the stock is owned by corporate insiders.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.